Traders should view this as a positive regulatory milestone that expands Exdensur's market potential in China, a critical region for respiratory therapeutics. The twice-yearly dosing differentiator may support uptake over competitors, potentially boosting GSK's respiratory franchise. Monitor upcoming sales figures in future earnings reports for commercial traction.
Price Chart
Executive Summary
GSK plc announced that its drug Exdensur (depemokimab) has been approved in China for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), following prior approval for severe asthma. This expands the drug's indications in a major market and reinforces its position as the first ultra-long-acting biologic for these conditions in China.
Key Facts
- Exdensur (depemokimab) approved in China for chronic rhinosinusitis with nasal polyps (CRSwNP).
- Approval based on ANCHOR-1 and ANCHOR-2 phase III trials showing statistically significant improvements in nasal polyp size and obstruction.
- Exdensur is the first and only ultra-long-acting biologic approved for CRSwNP in China, with dosing twice per year.
- Prior approval in China was granted for severe asthma in March 2026.
- The drug is also approved in the US, EU, UK, and Japan for severe asthma and/or CRSwNP.
Financial Impact
Positive revenue contribution expected from expanded indication in a key growth market; exact figures undisclosed but incremental to respiratory portfolio.
Risk Factors
- Commercial uptake may be slower than expected due to competition or reimbursement challenges.
- Forward-looking statements subject to risks outlined in GSK's 20-F, including regulatory and market access uncertainties.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-003334 |
| Document: 0001654954-26-003334-index-headers.html | 0001654954-26-003334 |
| Document: 0001654954-26-003334-index.html | 0001654954-26-003334 |
| Document: 0001654954-26-003334.txt | 0001654954-26-003334 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 10, 2026 19w ago | 6-K | $25.12 $25.25 | ▲ +0.52% | ▼ −1.62% | $26.12 (+3.98%) |
Jun 9, 2026 20w ago | 6-K | $24.66 $25.50 | ▲ +3.41% | ▲ +1.60% | $26.12 (+5.92%) |
Jun 9, 2026 20w ago | 6-K | $24.66 $25.50 | ▲ +3.41% | ▲ +1.60% | $26.12 (+5.92%) |
Jun 1, 2026 21w ago | 6-K | $24.25 $24.66 | ▲ +1.69% | ▲ +4.44% | $26.12 (+7.71%) |
Jun 1, 2026 21w ago | 6-K | $24.25 $24.66 | ▲ +1.69% | ▲ +4.44% | $26.12 (+7.71%) |
May 28, 2026 21w ago | 6-K | $24.58 $24.66 | ▲ +0.33% | ▲ +0.01% | $26.12 (+6.27%) |
May 27, 2026 21w ago | 6-K | $25.57 $23.94 | ▼ −6.37% | ▼ −7.58% | $26.12 (+2.15%) |
May 26, 2026 22w ago | 6-K | $25.50 $24.25 | ▼ −4.90% | ▼ −5.99% | $26.12 (+2.43%) |
May 26, 2026 22w ago | 6-K | $25.50 $24.25 | ▼ −4.90% | ▼ −5.99% | $26.12 (+2.43%) |
May 22, 2026 22w ago | 6-K | $26.00 $24.25 | ▼ −6.73% | ▼ −8.39% | $26.12 (+0.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers